Formulation and evaluation of baclofen liposome vesicles using lecithin
DOI:
https://doi.org/10.30827/ars.v61i3.15279Keywords:
Lecithin, Cholesterol, Baclofen, Ethanol, Muscle Relaxant Activity.Abstract
Introduction: The main aim of present study was to prepare and characterize liposomal formulation of baclofen to improve the effectiveness of the topically applied formulation.
Method: For the preparation of liposomes, different ratio of lecithin, cholesterol and ethanol were taken but ratio of drug and stearic acid were kept constant and prepared by ethanol injection method. Liposomes were characterized for vesicle size, vesicle shape, entrapment efficiency, in vitro studies, stability studies and in vivo studies.
Results: The average particle size of formulated liposome was in the range of 3.98±0.45-4.24±0.65 µm and small unilamellar vesicles with spherical in shape observed. Entrapment efficiency of optimized formulation was 58.67±0.81 %. The maximum % cumulative drug release behaviours were 67.66±5.32 % after 10 h. formulation stored in 4±2 °C temperature shows better stability (64.19±0.26) compared to elevated temperature. Swiss albino mice were used for the in vivo study and exhibit muscle relaxant activity in terms of no. of falls from rota rod apparatus (p value =0.001).
Conclusions: Baclofen loaded liposomal formulation have shown skeletal muscle relaxant activity in mice suggesting delivery of baclofen from liposomes in the therapeutic range.
Downloads
References
Bangham AD, Horne RW. Negative staining of phospholipids and their structured modofication by surface active agents as observed in the electron microscope, J Mol Biol. 1964; 8: 660–8. doi: 10.1016/s0022-2836(64)80115-7
Schreier H, Bouwstra J. Liposomes and niosomes as drug carriers: dermal and transdermal drug delivery. J Control Rel. 1994; 30: 1–5. doi: 10.1016/0168-3659(94)90039-6
Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, et al. Sterically stabilized liposomes improvement in pharmacokinetics and anti-tumor therapeutic efficacy. Proc Nutl Acad Sci. USA88, 1991; 11460-64. doi: 10.1073/pnas.88.24.11460
Freise CE, Hong K, Clemens LE, Papahadjopoulos D, Burke E,Martinez 0,Lake J,Ascher NL, Roberts JP. Characterization of a cyclosporine containing liposome. Transpla Proc.1991;23: 473-4.
Vadiei K, Lopez-Berestein G, Peres-Soler R, Luke DR. Tissue distribution and in vivo immunosuppressive activity of liposomal cyclosporine. Dru Metab Dispos. 1991; 19: 1147-51.
Lian T, Ho RJY. Trends and developments in liposome drug delivery systems. J Pharm Sci. 2001; 90: 667–80. doi: 10.1002/jps.1023.
Robinson JR, Lee HL. Controlled Drug Delivery Fundamentals and Applications. Marcel Decker, New York. 1987; 2: 524-52. doi: 10.1002/jps.2600770119.
Jain NK. Controlled and Novel drug delivery. CBS Publisher and distributor, 1997; 1: 100-26.
Gannu R, Vamshi YV, Kishan V, Rao YM. Development of Nitrendipine transdermal Patches: In vitro and Ex vivo Characterization. Curr Drug Del. 2007; 4: 69-76. doi: 10.2174/156720107779314767.
BruntonLL, Lazo JS, Parker KL. The pharmacological basis of therapeutics, Agent acting at the neuromuscular junction and autonomic gaglia. Mc Graw hill, New York, 2006; 11: 217. doi: 10.1136/oem.2007.033902
Kumar A, Badde S, Kamble R, Pokharkar VB. Development and characterization of liposomal drug delivery system fornimesulide. Int J Pharm Pharm Sci. 2010; 2(4): 87-9.
Varsheny HM, Tanwar YS, lowalekar R, Rathore KS. Designing and characterization of verapamil hydrochloride niosomes. Ind. Pharm. 2007; 6: 77-9.
Aggarwal D, Kaur IP. Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system. Int J Pharm. 2005; 290(1-2): 155-9. doi: 10.1016/j.ijpharm.2004.10.026.
Karki R, Mamatha GC, Subramanya G, Udupa N. Preparation, characterization and tissue diposition of niosomes containing isoniazide. Riverd Jew Cent. 2008; 1(2): 224-7.
Doijad RC, Manvi FV, Swathi S, Rony M. Niosomal drug delivery of cisplatin: development and characterization. Ind Drugs. 2008; 45(9): 713-8.
Vogel HG. Drug Discovery and Evaluation, Pharmacological Assays. 2nd. Ed. Springer-Verlag Berlin Heidelberg, New York, 2002; 398.
Downloads
Published
How to Cite
Issue
Section
License
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).